SCHEMBL4333751

SCHEMBL4333751

COc1ccc(Br)cc1I

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 1/20 0.44
TUBB P07437 1/20 0.44
TUBA3C P0DPH7 1/20 0.44
TUBA1B P68363 1/20 0.44
TUBA4A P68366 1/20 0.44
TUBB4B P68371 1/20 0.44
TUBB3 Q13509 1/20 0.44
TUBB2A Q13885 1/20 0.44
TUBB8 Q3ZCM7 1/20 0.44
TUBA3E Q6PEY2 1/20 0.44
TUBA1A Q71U36 1/20 0.44
TUBA1C Q9BQE3 1/20 0.44
TUBB6 Q9BUF5 1/20 0.44
TUBB2B Q9BVA1 1/20 0.44
TUBB1 Q9H4B7 1/20 0.44
TDP1 Q9NUW8 3/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
ALDH1A1 P00352 2/20 0.43
MAPK1 P28482 1/20 0.43
KDM4E B2RXH2 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30919640 1.00 TUBB4A (0.44) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL5972926 0.92 KMT2A (0.47) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL2836741 0.82 TSHR (0.42) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL30016613 0.82 TSHR (0.42) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL12526956 0.79 MAPT (0.39) TDP1L3MBTL1ALDH1A1MAPK1KDM4E
SCHEMBL20509 0.78 CA2 (0.56) TDP1L3MBTL1ALDH1A1MAPK1KDM4E
SCHEMBL29419589 0.78 CA2 (0.56) TDP1L3MBTL1ALDH1A1MAPK1KDM4E
SCHEMBL28833277 0.78 TSHR (0.39) TDP1L3MBTL1ALDH1A1MAPK1KDM4E
SCHEMBL481337 0.77 HTR2A (0.54) L3MBTL1ALDH1A1TSHRMAPTLMNA
SCHEMBL25354930 0.77 MAPK1 (0.39) TDP1L3MBTL1ALDH1A1MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4618755-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN Larkspur Biosciences, Inc. (US) 2025-09-24 EP disclosed
WO-2025049746-A1 COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME EIKON THERAPEUTICS, INC. (US) 2025-03-06 WO disclosed
CN-119219657-A Condensed ring compound for organic electroluminescent device 西安瑞联新材料股份有限公司 2024-12-31 CN disclosed
WO-2024107746-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN LARKSPUR BIOSCIENCES (US) 2024-05-23 WO disclosed
WO-2024107746-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN LARKSPUR BIOSCIENCES (US) 2024-05-23 WO disclosed
US-11770973-B2 Organic electroluminescence device and amine compound for organic electroluminescence device SAMSUNG DISPLAY CO., LTD. (KR) 2023-09-26 US disclosed
US-11770973-B2 Organic electroluminescence device and amine compound for organic electroluminescence device SAMSUNG DISPLAY CO., LTD. (KR) 2023-09-26 US disclosed
CN-109810110-B Compound with 2-aminopyrimidine structure, preparation method and application thereof 中国科学院上海药物研究所 2023-01-24 CN disclosed
CN-113121528-B Multi-target inhibition compound, composition, functional molecule and application thereof 中国科学院上海药物研究所 2022-12-13 CN disclosed
WO-2021143729-A1 COMPOUND, COMPOSITION AND FUNCTIONAL MOLECULE WITH MULTI-TARGET INHIBITING EFFECT AND USE THEREOF 中国科学院上海药物研究所 2021-07-22 WO disclosed
US-20140371201-A1 BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS AMGEN INC. 2014-12-18 US disclosed
WO-2014091368-A1 IMIDAZOPYRIDAZINE DERIVATIVES AS GABAA RECEPTOR MODULATORS PFIZER LIMITED (GB) 2014-06-19 WO disclosed
US-20140171435-A1 Chemical Compounds PFIZER LIMITED (GB) 2014-06-19 US disclosed
US-20120321533-A1 CATALYST ALMQVIST FREDRIK (SE) 2012-12-20 US disclosed
US-20120321533-A1 CATALYST ALMQVIST FREDRIK (SE) 2012-12-20 US disclosed
US-20100119424-A1 CATALYST ALMQUEST AB (SE) 2010-05-13 US disclosed
US-20100119424-A1 CATALYST ALMQUEST AB (SE) 2010-05-13 US disclosed
US-7612068-B2 Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives H. LUNDBECK A/S (DK) 2009-11-03 US disclosed
EP-1994983-A1 Catalyst containing covalently bonded formate groups and Pd(0) and process for its obtention Almquest AB (SE) 2008-11-26 EP disclosed
US-20060235003-A1 Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives H. LUNDBECK A/S (DK) 2006-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235003-A1 Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives TYR, TPST2, COMT TUBB4A 1030/4885TUBB 1686/4885TUBA3C 2122/4885
US-20140371201-A1 BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS SCN7A, TRPV1, TRPV5 TUBB4A 2024/4885TUBB 2295/4885TUBA3C 1321/4885
US-20140171435-A1 Chemical Compounds GABRA5, GABRA4, GABRA3 TUBB4A 1115/4885TUBB 1142/4885TUBA3C 766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.